Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma

Seminars in Hematology ◽

10.1053/shem.2001.26006 ◽

2001 ◽

Vol 38 (3) ◽

pp. 231-242 ◽

Cited By ~ 1

Author(s):

Athanasios Fassas ◽

Guido Tricot

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

High Dose ◽

Stem Cell Support ◽

Dose Treatment ◽

High Dose Treatment ◽

Cell Support

Download Full-text

A polymorphism in NFKB1 is associated with improved effect of interferon- maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support

Haematologica ◽

10.3324/haematol.2008.004572 ◽

2009 ◽

Vol 94 (9) ◽

pp. 1274-1281 ◽

Cited By ~ 20

Author(s):

A. J. Vangsted ◽

T. W. Klausen ◽

P. Gimsing ◽

N. F. Andersen ◽

N. Abildgaard ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Maintenance Treatment ◽

High Dose ◽

Stem Cell Support ◽

Dose Treatment ◽

High Dose Treatment ◽

Cell Support

Download Full-text

Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*

European Journal Of Haematology ◽

10.1111/j.1600-0609.2010.01465.x ◽

2010 ◽

Vol 85 (3) ◽

pp. 209-216 ◽

Cited By ~ 10

Author(s):

Annette J. Vangsted ◽

Tobias W. Klausen ◽

Niels F. Andersen ◽

Niels Abildgaard ◽

Anne O. Gang ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Population Based ◽

Late Relapse ◽

High Dose ◽

Population Based Study ◽

Stem Cell Support ◽

Dose Treatment ◽

High Dose Treatment ◽

Cell Support

Download Full-text

The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP

Annals of Hematology ◽

10.1007/s00277-010-1105-z ◽

2010 ◽

Vol 90 (6) ◽

pp. 675-684 ◽

Cited By ~ 9

Author(s):

Annette J. Vangsted ◽

Tobias Wirenfeldt Klausen ◽

Peter Gimsing ◽

Niels Abildgaard ◽

Niels F. Andersen ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Linkage Disequilibrium ◽

Linkage Disequilibrium Mapping ◽

High Dose ◽

Stem Cell Support ◽

Dose Treatment ◽

High Dose Treatment ◽

Cell Support

Download Full-text

Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma

Seminars in Hematology ◽

10.1016/s0037-1963(01)90015-0 ◽

2001 ◽

Vol 38 (3) ◽

pp. 231-242 ◽

Cited By ~ 17

Author(s):

Athanasios Fassas ◽

Guido Tricot

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

High Dose ◽

Stem Cell Support ◽

Dose Treatment ◽

High Dose Treatment ◽

Cell Support

Download Full-text

Early infections in patients undergoing high-dose treatment with stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma

Hematology ◽

10.1179/102453309x12583347113979 ◽

2010 ◽

Vol 15 (4) ◽

pp. 222-229

Author(s):

A. O. Gang ◽

M. Arpi ◽

Uffe J. O. Gang ◽

A. J. Vangsted

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Hodgkin Lymphoma ◽

High Dose ◽

Stem Cell Support ◽

Dose Treatment ◽

Non Hodgkin Lymphoma ◽

High Dose Treatment ◽

Cell Support

Download Full-text

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

European Journal Of Haematology ◽

10.1034/j.1600-0609.2001.066005328.x ◽

2001 ◽

Vol 66 (5) ◽

pp. 328-336 ◽

Cited By ~ 27

Author(s):

Nina Gulbrandsen ◽

Finn Wisløff ◽

Erik Nord ◽

Stig Lenhoff ◽

Martin Hjorth ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Autologous Blood ◽

Cost Utility ◽

Cost Utility Analysis ◽

High Dose ◽

Utility Analysis ◽

Stem Cell Support ◽

High Dose Melphalan ◽

Cell Support

Download Full-text

Outcome for Patients with Leukemia, Multiple Myeloma and Lymphoma who Relapse After High Dose Therapy and Autologous Stem Cell Support

Leukemia & Lymphoma ◽

10.3109/10428199609045716 ◽

1996 ◽

Vol 24 (1-2) ◽

pp. 81-91 ◽

Cited By ~ 11

Author(s):

H. E. Johnsen ◽

B. Björkstrand ◽

K. Carlson ◽

A. Gruber ◽

A. Blystad ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

High Dose ◽

High Dose Therapy ◽

Stem Cell Support ◽

Dose Therapy ◽

Cell Support

Download Full-text

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

Experimental Hematology and Oncology ◽

10.1186/s40164-018-0110-0 ◽

2018 ◽

Vol 7 (1) ◽

Cited By ~ 4

Author(s):

Henrik Gregersen ◽

Trung Do ◽

Ida Bruun Kristensen ◽

Ulf Christian Frølund ◽

Niels Frost Andersen ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Phase Ii ◽

Induction Therapy ◽

Phase Ii Study ◽

High Dose ◽

Newly Diagnosed ◽

Stem Cell Support ◽

High Dose Melphalan ◽

Cell Support

Download Full-text

Multiple myeloma, high-dose treatment and autologous stem cell transplantation—current status

Medical Oncology ◽

10.1007/bf02988838 ◽

1996 ◽

Vol 13 (1) ◽

pp. 23-30 ◽

Cited By ~ 3

Author(s):

Bo Björkstrand

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Current Status ◽

High Dose ◽

Dose Treatment ◽

High Dose Treatment

Download Full-text

21 / miRNAs as indices predicting early toxicity in high-dose melphalan chemotherapy followed by autologous stem cell support in multiple myeloma patients.

10.26226/morressier.5b3b802db1b87b000eceda36 ◽

2018 ◽

Author(s):

Szeremet Agnieszka

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

High Dose ◽

Stem Cell Support ◽

High Dose Melphalan ◽

Early Toxicity ◽

Cell Support

Download Full-text